A Phase II Clinical Study Evaluating SLN12140 in Complement Inhibitor-Naïve Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria
Latest Information Update: 13 Feb 2026
At a glance
- Drugs SLN 12140 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Sponsors Linno Pharmaceuticals
Most Recent Events
- 13 Feb 2026 New trial record